BiondVax vaccine meets Phase II influenza endpoint

BiondVax Pharmaceuticals Ltd. (Tel Aviv:BNDX) said its Multimeric-001 Universal Flu Vaccine met the co-primary endpoint of significantly increasing IgG antibodies from baseline to day 42 vs. adjuvanted placebo (p<0.05) in a Phase IIa trial to vaccinate against influenza virus. On the co-primary safety endpoint, the vaccine was well tolerated with no severe adverse events reported. The double-blind, Israeli trial enrolled 200 healthy volunteers. The vaccine consists of nine conserved linear epitopes taken in triplicate from hemagglutinin (HA), nucleoprotein (NP) and matrix proteins of the influenza virus. ...